Stick­ing to hottest trends in bio­phar­ma, On­colo­gie gath­ers $80M for next leg of trans-Pa­cif­ic clin­i­cal jour­ney

When On­colo­gie launched last year, it high­light­ed its trendy mod­el of op­er­at­ing be­tween Boston and Shang­hai amid a wave of Chi­nese cap­i­tal ea­ger to back ex­pe­ri­enced US ex­ecs in de­vel­op­ing West­ern can­cer drugs for the Asian mar­ket. For its Se­ries B, it’s al­ly­ing it­self with an­oth­er buzzy con­cept in the in­dus­try — choos­ing the right pa­tients by bio­mark­ers.

Nan Fung Life Sci­ences and Piv­otal BioVen­tures Chi­na came back to lead the $80 mil­lion round de­signed to speed up clin­i­cal de­vel­op­ment as well as ramp­ing up part­ner­ing and ac­qui­si­tion of new as­sets, ac­cord­ing to CEO Lau­ra Ben­jamin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER